U.S. Patent Office issues “Vanda Memo”
U.S. Patent Office issues “Vanda Memo” to clarify how the USPTO is determining subject matter eligibility following the decision in Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals, and specifically, provides guidance as to whether claims are “directed to” a judicial exception.